Werewolf Therapeutics initiated with a Buy at EF Hutton

EF Hutton analyst Michael King initiated coverage of Werewolf Therapeutics with a Buy rating and $8.30 price target. Werewolf is an "emerging leader" in the area of engineered cytokines for immuno-therapy of cancer and autoimmune conditions, said King, who adds that the company’s PREDATOR platform is designed to overcome the shortcomings of the compounds that came before its clinical stage candidates WTX-124 and WTX-330.